The development of the next generation of Alzheimer’s disease drugs is becoming essential to face up to this challenge. At CTAD 2014 we learned of new pathways identified with tau biomarkers as well as molecular and functional imaging markers in AD secondary prevention trials, non-pharmacological clinical trials to prevent Alzheimer’s disease, health economics outcomes in preventive AD trials as well as experiences of many teams involved directly in the AD clinical trial process from animal models to Phase III and IV trials. This year again CTAD 2015 has designed its program around these core themes ranging from Imaging, Biomarkers and Cognitive Endpoints, to Health Economics, Epidemiology and New Therapies.
- This event has passed.
Clinical Trials on Alzheimer’s Disease (CTAD)
November 5, 2015 - November 7, 2015
Join Cogstate in Barcelona for CTAD 2015. Alzheimer’s disease is one of the most important health challenges worldwide and CTAD 2015 has designed its program around these critical core themes ranging from Imaging, Biomarkers and Cognitive Endpoints, to Health Economics, Epidemiology and New Therapies.